Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O14508
UPID:
SOCS2_HUMAN
Alternative names:
Cytokine-inducible SH2 protein 2; STAT-induced STAT inhibitor 2
Alternative UPACC:
O14508; A8K3D1; O14542; O95102; Q9UKS5
Background:
Suppressor of cytokine signaling 2 (SOCS2), also known as Cytokine-inducible SH2 protein 2 and STAT-induced STAT inhibitor 2, plays a pivotal role in the negative regulation of cytokine signal transduction. It is particularly involved in the growth hormone/IGF1 signaling pathway, acting as a probable substrate recognition component of a SCF-like ECS E3 ubiquitin-protein ligase complex. This complex is crucial for the ubiquitination and proteasomal degradation of target proteins.
Therapeutic significance:
Understanding the role of Suppressor of cytokine signaling 2 could open doors to potential therapeutic strategies.